Background {#Sec1}
==========

Static lung hyperinflation is one of the significant challenges in patients with COPD. It is characterised by a decrease in the elastic recoil of the lungs with a premature closure of small airways leading to air trapping. The impact on lung function parameters is expressed by an increase in functional residual capacity (FRC) and a progressive decrease in inspiratory reserve volume and inspiratory capacity (IC). During exercise, dynamic compression of the airways intensifies and this results in increased dynamic hyperinflation, leading to further exercise limitation \[[@CR1]\]. The major clinically relevant mechanism of action of long-acting bronchodilators in COPD is related to the reduction of hyperinflation \[[@CR1]--[@CR5]\], which can be assessed by improvements in IC \[[@CR6]\]. Whereas short-acting bronchodilators are used for immediate relief from symptoms, one or more long-acting bronchodilators (long-acting β~2~-agonists \[LABAs\], e.g., indacaterol maleate \[IND\], and long-acting muscarinic antagonists \[LAMAs\], e.g., glycopyrronium bromide \[GLY\]) are recommended for long-term maintenance therapy in patients with moderate-to-severe COPD \[[@CR7]\]. Since LABAs and LAMAs have different mechanisms of action, they may exert additive bronchodilation effects when used together. This suggests that IND and GLY could be used in combination to optimise and maximise bronchodilation in patients with COPD whose needs are not adequately met by LABA or LAMA monotherapy \[[@CR8]--[@CR10]\]. However, there are limited data on the effects of a combination of two long-acting bronchodilators on body plethysmography lung function parameters in patients with COPD \[[@CR11]\].

In this study we evaluated the efficacy and safety of the free combination of IND + GLY versus IND alone on lung function parameters evaluated by body plethysmography, including inspiratory capacity (IC), forced expiratory volume in 1 s (FEV~1~), forced vital capacity (FVC), total lung capacity (TLC) and airway resistance (Raw), in patients with moderate-to-severe COPD.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The study was conducted in 11 centres in Switzerland between November 2012 and June 2014, and included a total of 78 eligible patients who were randomised to one of two treatment sequences. The study protocol was reviewed and approved by institutional review boards and ethics committees.

Eligible patients were adults aged ≥40 years with a diagnosis of moderate or severe COPD according to GOLD criteria \[[@CR12]\] who had signed an informed consent form, and fulfilling the following: smoking history of at least 10 pack-years \[both current and ex-smokers\]; post-bronchodilator FEV~1~ \<80% and ≥30% of the predicted value, and post-bronchodilator FEV~1~/FVC \<70%. The main exclusion criteria were COPD exacerbations requiring systemic glucocorticoid treatment or antibiotics and/or hospitalisation or a history of respiratory tract infection within 6 weeks prior to screening, concomitant pulmonary disease other than COPD, history of asthma or lung cancer, a known history of alpha-1 antitrypsin deficiency, or a history of hypersensitivity to any of the study medications or to medications from similar drug classes.

Study design and treatment {#Sec4}
--------------------------

This was a multicentre, randomised, double-blind, single-dose, cross-over, placebo-controlled study to assess the effect of a single-dose combination of inhaled IND (150 μg) + GLY (50 μg) versus inhaled IND (150 μg) + placebo (corresponding GLY placebo) on static hyperinflation (Fig. [1](#Fig1){ref-type="fig"}). Patients had lung function assessments (spirometry) at each study visit and body plethysmography at Visits 2 and 3. Safety assessments included physical examinations, vital signs, and monitoring of adverse events (AEs) and serious adverse events (SAEs). All patients prematurely withdrawing from the study underwent study completion evaluations.Fig. 1Study design

Study objectives {#Sec5}
----------------

The primary objective was to demonstrate superiority of a single dose of the combined inhalation of IND + GLY versus IND alone on peak-IC, defined as the maximum value within 4 h of inhalation. The key secondary objective was to compare the efficacy of IND + GLY versus IND in terms of FEV~1~ over 4 h (30, 60, 120, 180 and 240 min) post dosing. Other secondary objectives were to compare the efficacy of IND + GLY versus IND on IC, FVC, and airway resistance (Raw) over 4 h (30, 60, 120, 180 and 240 min) after dosing.

Statistical analysis {#Sec6}
--------------------

### Sample size calculation {#Sec7}

With regard to peak-IC, a sample size of 69 patients was expected to provide 80% power to detect a difference of 0.12 L in IC at peak between the groups, assuming a standard deviation of differences of 0.35 L (test level α = 0.025 one-sided or α = 0.05 two-sided). Assuming a dropout rate of approximately 10%, a total of \~78 patients had to be randomised to ensure that at least 70 patients completed the study. Regarding FEV~1~, a sample size of 70 patients provided 99% power to detect a difference of 0.18 L in FEV~1~ mean values between the groups.

The intention to treat (ITT, full analysis set \[FAS\]) population consisted of all randomised patients who received at least one dose of study medication and had at least one post-baseline assessment of the primary efficacy variable. The per-protocol (PP) population consisted of all patients in the ITT population without major protocol violations or who discontinued the study due to treatment-related reasons. A supportive analysis on the PP population was performed for the primary endpoint peak-IC and the key secondary endpoint FEV~1~. The safety population (full analysis set; FAS) was defined as all randomised patients who received at least one dose of study medication with at least one post-baseline safety assessment.

Study endpoints were analysed by an analysis of covariance (ANCOVA) model with treatment sequence (AB or BA) and treatment as fixed effects, the lung function parameter as a covariate and patient as a random effect. Treatment effect was estimated as the contrast of the treatment effect in the statistical model and presented as point estimates and corresponding 95% two-sided confidence intervals (CIs). The null hypothesis for the primary analysis was that combination of IND + GLY is not superior to IND alone regarding the lung function parameters. The alternative hypothesis was that treatment with a combination of IND + GLY is superior to IND alone. The null hypothesis was rejected in favour of the alternative hypothesis if the 95% CI of the least squares means treatment contrast of the difference "combination therapy --- single therapy" was greater than 0 in its entirety. This corresponds to a planned alpha error of 5% two-sided or 2.5% one-sided. An interim analysis was performed after 20 patients had completed Visit 3. No adjustments were needed.

Results {#Sec8}
=======

The mean ± SD age of the patients was 64.8 ± 8.4 years (Table [1](#Tab1){ref-type="table"}), 59.2% were male, all Caucasian, and 24 (31.2%) current smokers. Mean time since COPD diagnosis was 5.2 ± 5.2 years. The mean FEV~1~% predicted was 56 ± 13 and 38.7% of patients had a GOLD stage of III or above. The mean total lung capacity (TLC) was 120.68 ± 18.75% pred. and the mean Raw was 210.99 ± 117.11% pred. The patient disposition and randomisation is given in Fig. [2](#Fig2){ref-type="fig"}.Table 1Demography and baseline characteristics (ITT population, *N* = 76)Mean (SD), *N* = 76Age at informed consent, years64.80 (8.39)Height, cm168.22 (8.55)Weight, kg75.45 (15.52)BMI, kg/m^2^26.65 (5.05)Smoking history\
Number of pack-years, years50.13 (23.28)Years since COPD diagnosis5.17 (5.24)Age at COPD diagnosis, years60.16 (10.96)FEV~1~ % predicted56.09 (13.28)FEV~1~\*, L1.50 (0.45)FVC\*, L2.95 (0.89)IC, L2.45 (0.69)Total Lung Capacity (TLC), L7.13 (1.42)TLC % of predicted normal value120.68 (18.75)Airway Resistance (Raw)6.73 (3.19)Raw % of predicted normal value210.99 (117.11)Hyperinflation IC/TLC0.35 (0.09)N (%)GenderMale45 (59.2)Female31 (40.8)Number of patients with current medical conditionCAD7 (9.2)Hypertension29 (38.2)Diabetes mellitus4 (5.3)Number of patients according COPD GOLD-stageStage I8 (10.5)Stage II31 (40.8)Stage III30 (39.5)Stage IV7 (9.2)*ITT* intention to treat, *N/n* number of patients, *BMI* body mass index, *SD* standard deviation, *COPD* chronic obstructive pulmonary disease, *FEV* ~*1*~ forced expiratory volume in 1 s, *FVC* forced vital capacity, *IC* inspiratory capacity, *CAD* coronary artery disease, GOLD stage defined as: stage I = FEV~1~/FVC \<70% and FEV~1~ ≥80% predicted; stage II = FEV~1~/FVC \<70% and 50% ≤FEV~1~ \<80% predicted; stage III = FEV~1~/FVC \<70% and 30% ≤FEV1 \<50% predicted; stage IV = FEV~1~/FVC \<70% and FEV~1~ \<30% predicted^\*^ *N* = 75 Fig. 2Disposition of patients

The combination of IND + GLY versus IND presented a numerically higher peak-IC (2.95 L versus 2.88 L), with an adjusted treatment difference (Δ) of 0.076 L (95% −0.010 -- 0.161 L; *p* = 0.083) (Fig. [3a](#Fig3){ref-type="fig"}). IND + GLY presented also a statistically significant difference in mean IC over 4 h versus IND (2.76 L versus 2.70 L; Δ = 0.054 L, 95% CI 0.022 -- 0.086 L; *p* = 0.001) (Fig. [3b](#Fig3){ref-type="fig"}). FEV~1~, FVC and Raw, but not TLC, were significantly improved by IND + GLY compared to IND alone. A statistically significant adjusted treatment difference in FEV~1~ was noted at all time points in favour of IND + GLY treatment (*p* \<0.001 for all comparisons), reaching a peak difference of Δ = 0.099 L (95%CI 0.060 -- 0.139 L) at 120 min post-dose (Fig. [4a](#Fig4){ref-type="fig"}). Similarly, IND + GLY resulted in higher FVC mean values at all time points after a single-dose inhalation (*p* \<0.01 for all comparisons), reaching a peak difference of Δ = 0.163 L (95%CI 0.092 -- 0.234 L) at 240 min post-dose (Fig. [4b](#Fig4){ref-type="fig"}). Raw measurements were consistently lowered by IND + GLY treatment at all time points after the single-dose inhalation (p \<0.001 for all comparisons), reaching a peak difference of Δ = -0.667 cmH~2~O/L/sec (95%CI -0.928 -- -0.406 cmH2O/L/sec) at 240 min post-dose (Fig. [4c](#Fig4){ref-type="fig"}), in favour of dual bronchodilation (*p* ≤0.001). There were no differences in TLC between the study treatments.Fig. 3Improvements in **a** Peak Inspiratory Capacity (peak-IC) \[L\] (*N* = 74) and (**b**) Mean inspiratory Capacity \[L\] (*N* = 77) by IND + GLY versus IND alone Fig. 4**a** Forced expiratory volume in 1 s (FEV1) \[L\] over time (ITT population, *N* = 77); **b** Forced vital capacity (FVC) \[L\] (*N* = 77); **c** Airway resistance (Raw) \[cmH2O/L/s\] (*N* = 77)

Safety {#Sec9}
------

Eight (10.4%) patients experienced treatment-emergent adverse events (TEAEs) (Table [2](#Tab2){ref-type="table"}). No patient died in the course of the study or experienced any treatment-emergent SAE. According to the investigators' assessment, a relation to study medication was not suspected for any of the TEAEs. The intensity of TEAEs was mostly mild (6 patients) or moderate (2 patients). Prior to the first dose of study medication, one patient experienced atrial fibrillation of moderate intensity. In conclusion, the treatments were well tolerated with a good safety profile.Table 2Incidence of TEAEs by primary system organ class (safety population, *N* = 77)Combined treatment (IND + GLY)IND alone (IND + placebo)AllPrimary system organ class*N* = 77, n (%)*N* = 77, n (%)*N* = 77, n (%)Number (%) of patients with at least one AE5 (6.5)3 (3.9)8 (10.4)Investigations1 (1.3)2 (2.6)3 (3.9)Respiratory, thoracic & mediastinal disorders2 (1.3)1 (1.3)3 (3.9)Infections & infestations1 (1.3)01 (1.3)Musculoskeletal and connective tissue disorders1 (1.3)01 (1.3)*TEAEs* treatment-emergent adverse events, *IND* indacaterol, *IND + GLY* indacaterol and glycopyrronium, *N or n* number of patients, *AE* adverse event

Discussion {#Sec10}
==========

In this prospective, randomised study we showed that the combination of two long-acting bronchodilators provided a greater improvement in lung hyperinflation and lung function parameters compared to a single long-acting agent. Specifically, IND + GLY provided a numerical improvement in peak-IC combined with a statistically significant difference in mean IC over 4 h compared to IND monotherapy. Additionally, the treatment with IND + GLY resulted in consistent statistically significant improvements in FEV~1~, FVC and Raw compared to IND alone. The two treatments presented a similar safety profile.

As a unique feature of the trial, the use of body plethysmography allowed us to observe the significant difference in Raw in favour for IND + GLY in this study. Raw is not frequently reported in studies evaluating the effect of bronchodilators in COPD. However, this parameter is suggested to be sensitive and to reflect airflow obstruction, particularly of the peripheral airways, more accurately than the FEV~1~/FVC ratio. In assessing the acute functional effect of bronchodilators, specific Raw change-based criteria may be preferable to FEV~1~- or FVC-based criteria, being more closely related to bronchodilator-induced improvements in lung mechanics and dyspnoea at rest \[[@CR13]\]. Raw measurements were strongly improved by IND + GLY treatment compared to IND monotherapy at all time points after single-dose inhalation.

A possible explanation of the non-statistically significant result in SYNERGY on peak-IC might be attributed to the high variability of this measurement. This is supported by the fact that in contrast to the peak-IC measurement, the adjusted mean IC in the SYNERGY study (which included several values) presented a statistically significant difference between the two treatments. Additionally, the results of the present study are consistent with those of other published studies that have investigated the efficacy and safety of LABA/LAMA combination therapy in patients with COPD \[[@CR7], [@CR11], [@CR14]--[@CR18]\]. In order to allow for higher power and better generalisability of the results, we additionally evaluated with a similar analysis as in SYNERGY the peak-IC and FEV~1~ in a pooled analysis of patient-level data (*n* = 1,548) from 3 studies that evaluated the combination of IND + GLY versus IND, i.e. SYNERGY (present study), SHINE \[[@CR14]\] and GLOW6 \[[@CR7]\] (see details in the Additional file [1](#MOESM1){ref-type="media"} Online Supplement). Mean adjusted peak-IC in this pooled analysis was statistically significantly higher for patients treated with IND + GLY versus IND alone (Δ = 0.075 L; 95% CI 0.040 -- 0.109 L; *p* ≤0.001) (Additional file [2](#MOESM2){ref-type="media"} Figure S1). Additionally, FEV~1~ was statistically significantly higher for IND + GLY versus IND at 30, 120 and 240 min after a single dose inhalation, with a maximal difference at 120 min (Δ = 0.094 L; 95% CI 0.076 -- 0.112 L; *p* ≤0.001) (Additional file [3](#MOESM3){ref-type="media"} Figure S2). These results further support the reduction of static hyperinflation, as expressed by IC, by a combination of two bronchodilators compared to a single agent.

The physiological and clinical significance of these results can be attributed to prolonged maximal bronchodilation that minimises air trapping and leads to effective reduction of static and dynamic lung hyperinflation. Improved IC is associated with improved exercise endurance and dyspnoea \[[@CR2], [@CR3]\] and potentially improved long-term outcomes. Casanova et al. showed that lung hyperinflation, as expressed by the IC/TLC ratio, is an independent predictor of mortality \[[@CR19]\]. Furthermore, Tantucci et al. identified IC as a powerful functional predictor of all-cause and respiratory mortality and of exacerbation-related hospital admissions in patients with COPD \[[@CR20]\].

The improvement in bronchodilation and measures of hyperinflation observed in the present study is supported by data from the BRIGHT study (IND/GLY fixed-dose combination versus placebo and tiotropium), which showed significantly improved dynamic IC, trough FEV~1~, residual volume (RV) and FRC in patients with moderate-to-severe COPD receiving IND/GLY that were accompanied by increased exercise endurance \[[@CR11]\]. Mahler et al. showed that IND + tiotropium provided greater bronchodilation and lung deflation compared with tiotropium monotherapy \[[@CR17]\]. To what extent these effects have a clinically significant impact on outcomes other than lung function and exercise endurance requires further evaluation. However, there is significant evidence that exacerbations, the relevant trigger for progression, are more effectively prevented by IND + GLY than by a single long-acting bronchodilator \[[@CR21]\].

We acknowledge that there were limitations in the study. These include the cross-over study design, the short study duration, and the potentially limited patient population due to the clinical trial settings. Additionally, we need to acknowledge that in patients with severe airflow limitation, the plethysmographic Raw may be of limited validity. Finally, post hoc it became obvious that possibly the initially taken assumptions for the power calculations were overestimated, resulting in a relatively small sample size to reach statistical significance. This is supported by the results of the pooled analysis showing the statistical significance for peak-IC.

In our study all treatments were equally well tolerated and showed a good safety profile, which is also documented in multiple clinical trials and the use in clinical practice \[[@CR7], [@CR8], [@CR10], [@CR11], [@CR14], [@CR16], [@CR17], [@CR21]\].

Conclusions {#Sec11}
===========

In summary, the results of the present study show that treatment with IND + GLY had a stronger beneficial effect on lung hyperinflation and airflow obstruction parameters in patients with COPD than treatment with IND alone. The treatment was well tolerated and had a good safety profile. These data support the use of dual bronchodilator therapy to not only improve airway calibre (FEV~1~) but also decrease hyperinflation and its associated negative consequences in patients with COPD.
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Summary {#FPar7}
=======

Indacaterol and glycopyrronium showed a stronger beneficial effect on body plethysmography measurements in patients with COPD than indacaterol alone.
